在BRCA携带者早期乳腺癌的临床管理
Bruno Muñante1, Roberto Paz-Manrique2, Joseph A Pinto3
1Oncosalud, AUNA, Lima, Peru.
Cancer control : journal of the Moffitt Cancer Center
|September 19, 2025
概括
在BRCA突变携带者中管理早期乳腺癌需要个性化护理. 在PARP抑制剂和风险适应性手术方面的进展改善了结果,但针对性查和监测对这一高风险群体至关重要.
科学领域:
- 在瘤学瘤学.
- 遗传学 遗传学 是一个
- 医疗成像医学成像
背景情况:
- 携带BRCA1/2突变的乳腺癌带来了独特的挑战,包括瘤生物学和风险增加.
- 拉丁美洲的BRCA患病率具有变化,因此需要针对特定地区的基因查策略.
研究的目的:
- 审查和综合当前关于管理BRCA突变载体早期乳腺癌的证据.
- 突出需要区域特定的基因查和定制管理方法.
主要方法:
- 对治疗策略,成像和手术管理的证据进行系统审查.
- 分析临床试验数据 (例如OlympiA,KEYNOTE-522) 和观察性研究.
- 考虑特定人群,包括跨性别人士.
主要成果:
- 像Olaparib这样的PARP抑制剂在BRCA载体中显示出生存益处.
- 由于BRCA1携带者的乳房图像难以捉摸的瘤,MRI被青用于成像;缩短的协议提供了效率.
- 风险适应性手术 (乳房切除 vs 乳房保护手术) 需要仔细考虑对侧面癌症风险.
- 新辅助化疗显示出有前途的结果,特别是在三阴性亚型.
结论:
- 优化对BRCA载体的护理需要多学科,个性化战略,整合遗传,区域和临床因素.
- 共同决策和持续的研究对于解决幸存者问题和确保公平照顾至关重要.
更多相关视频
08:34Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
20.9K
08:15gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair
Published on: October 6, 2014
12.6K
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Cancer Survival Analysis
650
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
650
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
